CCP
KYMR icon

Clough Capital Partners’s Kymera Therapeutics KYMR Stock Holding History

Clough Capital Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,925
Closed -$850K – 112
2025
Q4 		$850K Buy
+10,925
New +$738K 0.08% 105
2022
Q2 		– Sell
-185,700
Closed -$7.86M – 106
2022
Q1 		$7.86M Sell
185,700
-85,300
-31% -$3.6M 0.6% 57
2021
Q4 		$17.2M Hold
271,000
– – 1.15% 27
2021
Q3 		$15.9M Buy
271,000
+170,400
+169% +$9.88M 0.97% 42
2021
Q2 		$4.88M Buy
+100,600
New +$4.37M 0.27% 77

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Clough Capital Partners's KYMR Position: Q1 2026 in Review

Clough Capital Partners sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 10,925 shares — an estimated $850K sold.

Clough Capital Partners first reported a position in KYMR in Q2 2021 and held it in 5 quarters. The position peaked at $17.2M in Q4 2021. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Clough Capital Partners reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Clough Capital Partners sold 10,925 Kymera Therapeutics shares in Q1 2026, an estimated $850K.
  • Clough Capital Partners first reported a position in Kymera Therapeutics in Q2 2021 and held it in 5 quarters.
  • Clough Capital Partners's Kymera Therapeutics position peaked at $17.2M in Q4 2021.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Clough Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.